Travere Therapeutics (TVTX) Research & Development (2016 - 2025)
Historic Research & Development for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $51.9 million.
- Travere Therapeutics' Research & Development rose 40.83% to $51.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $210.2 million, marking a year-over-year decrease of 230.84%. This contributed to the annual value of $217.5 million for FY2024, which is 1122.25% down from last year.
- According to the latest figures from Q3 2025, Travere Therapeutics' Research & Development is $51.9 million, which was up 40.83% from $49.4 million recorded in Q2 2025.
- Travere Therapeutics' Research & Development's 5-year high stood at $66.5 million during Q2 2023, with a 5-year trough of $46.9 million in Q1 2025.
- Moreover, its 5-year median value for Research & Development was $54.3 million (2024), whereas its average is $54.9 million.
- In the last 5 years, Travere Therapeutics' Research & Development surged by 6825.92% in 2021 and then crashed by 1829.09% in 2024.
- Quarter analysis of 5 years shows Travere Therapeutics' Research & Development stood at $53.0 million in 2021, then increased by 9.6% to $58.1 million in 2022, then rose by 2.86% to $59.7 million in 2023, then rose by 3.88% to $62.1 million in 2024, then decreased by 16.4% to $51.9 million in 2025.
- Its Research & Development was $51.9 million in Q3 2025, compared to $49.4 million in Q2 2025 and $46.9 million in Q1 2025.